FDA: Potential for opioids to be in Novartis OTC products in mix-up
This article was originally published in Scrip
Executive Summary
The consumer-level recall Novartis issued for its over-the-counter (OTC) medicines Excedrin, NoDoz, Bufferin and Gas-X could be much more dangerous than the company disclosed in an 8 January weekend statement, with US regulators revealing that there is the potential that prescription opioids, such as Endo Pharmaceuticals' Opana ER (oxymorphone hydrochloride extended-release) and Percocet (oxycodone hydrochloride and acetaminophen), could have ended up in the bottles of the OTC drugs.